PMM.02 Association of the history of maternal-placental syndrome and cardiovascular disease in women with systemic lupus erythematosus: Abstract PMM.02 Table

Women account for roughly 90% of patients with systemic lupus erythematosus (SLE) and they are typically diagnosed when they are in their childbearing age. Patients with SLE are at increased risk of premature cardiovascular disease (CVD) representing the major cause of morbidity and mortality in this patient group. Premature CVD is significantly pronounced in women with SLE who have a history of pre-eclampsia compared to those who have no history of pre-eclampsia. Therefore, the prevention of future CVD is particularly important in women with a previous pregnancy history complicated by pre-eclampsia. Patients worry about the possible risk for future CVD.

Download Full-text

Systemic lupus erythematosus

Practical management of the pregnant patient with rheumatic disease ◽

10.1093/med/9780198845096.003.0013 ◽

2021 ◽

pp. 157-161

Author(s):

Karen Schreiber ◽

Monika Østensen

Keyword(s):

Systemic Lupus Erythematosus ◽

Cardiovascular Disease ◽

Patient Group ◽

Lupus Erythematosus ◽

Childbearing Age ◽

Systemic Lupus ◽

Previous Pregnancy ◽

Premature Cardiovascular Disease ◽

Increased Risk ◽

History Of

Women account for roughly 90% of patients with systemic lupus erythematosus (SLE) and they are typically diagnosed when they are in their childbearing age. Patients with SLE are at increased risk of premature cardiovascular disease (CVD) representing the major cause of morbidity and mortality in this patient group. Premature CVD is significantly pronounced in women with SLE who have a history of pre-eclampsia compared to those who have no history of pre-eclampsia. Therefore, the prevention of future CVD is particularly important in women with a previous pregnancy history complicated by pre-eclampsia. Patients worry about the possible risk for future CVD.

Download Full-text

“Protenuria in SLE: Is it always lupus?”

Lupus ◽

10.1177/0961203320983458 ◽

2021 ◽

pp. 096120332098345

Author(s):

Alessandra Ida Celia ◽

Roberta Priori ◽

Bruna Cerbelli ◽

Francesca Diomedi-Camassei ◽

Vincenzo Leuzzi ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Lupus Nephritis ◽

Fabry Disease ◽

Histological Examination ◽

Lupus Erythematosus ◽

Systemic Lupus ◽

Kidney Involvement ◽

History Of ◽

Genetic Assay

Proteinuria is one of the most typical manifestations of kidney involvement in Systemic Lupus Erythematosus (SLE). We report the case of a 23-year-old woman with a 6-year-long history of SLE presenting with proteinuria after a three-year remission on hydroxychloroquine. Kidney histological examination showed alterations inconsistent with lupus nephritis and suggestive of hydroxychloroquine toxicity or Fabry disease. The latter was confirmed by genetic assay.

Download Full-text

Semiquantified Noncalcified Coronary Plaque in Systemic Lupus Erythematosus

The Journal of Rheumatology ◽

10.3899/jrheum.120197 ◽

2012 ◽

Vol 39 (12) ◽

pp. 2286-2293 ◽

Cited By ~ 14

Author(s):

ADNAN N. KIANI ◽

JENS VOGEL-CLAUSSEN ◽

ARMIN ARBAB-ZADEH ◽

LAURENCE S. MAGDER ◽

JOAO LIMA ◽

...

Keyword(s):

Risk Factors ◽

Systemic Lupus Erythematosus ◽

Cardiovascular Risk ◽

Cardiovascular Risk Factors ◽

Lupus Erythematosus ◽

Univariate Analysis ◽

Coronary Plaque ◽

Systemic Lupus ◽

History Of ◽

Noncalcified Plaque

Objective.A major cause of morbidity and mortality in systemic lupus erythematosus (SLE) is accelerated coronary atherosclerosis. New technology (computed tomographic angiography) can measure noncalcified coronary plaque (NCP), which is more prone to rupture. We report on a study of semiquantified NCP in SLE.Methods.Patients with SLE (n = 147) with no history of cardiovascular disease underwent 64-slice coronary multidetector computed tomography (MDCT). The MDCT scans were evaluated quantitatively by a radiologist, using dedicated software.Results.The group of 147 patients with SLE was 86% female, 70% white, 29% African American, and 3% other ethnicity. The mean age was 51 years. In our univariate analysis, the major traditional cardiovascular risk factors associated with noncalcified plaque were age (p = 0.007), obesity (p = 0.03; measured as body mass index), homocysteine (p = 0.05), and hypertension (p = 0.04). Anticardiolipin (p = 0.026; but not lupus anticoagulant) and anti-dsDNA (p = 0.03) were associated with higher noncalcified plaque. Prednisone and hydroxychloroquine therapy had no effect, but methotrexate (MTX) use was associated with higher noncalcified plaque (p = 0.0001). In the best multivariate model, age, current MTX use, and history of anti-dsDNA remained significant.Conclusion.Our results suggest that serologic SLE (anti-dsDNA) and traditional cardiovascular risk factors contribute to semiquantified noncalcified plaque in SLE. The association with MTX is not understood, but should be replicated in larger studies and in multiple centers.

Download Full-text

An Early Unexpected Immune Thrombotic Thrombocytopenic Purpura Relapse Associated with SARS-CoV-2 Infection: A Case Report and Literature Review

Acta Haematologica ◽

10.1159/000514283 ◽

2021 ◽

pp. 1-5

Author(s):

Maya Kornowski Cohen ◽

Liron Sheena ◽

Yair Shafir ◽

Vered Yahalom ◽

Anat Gafter-Gvili ◽

...

Keyword(s):

Systemic Lupus Erythematosus ◽

Case Report ◽

Thrombotic Thrombocytopenic Purpura ◽

Lupus Erythematosus ◽

Response To Therapy ◽

Intravascular Hemolysis ◽

Systemic Lupus ◽

Thrombocytopenic Purpura ◽

History Of ◽

Triggering Factor

SARS-CoV-2 has been reported as a possible triggering factor for the development of several autoimmune diseases and inflammatory dysregulation. Here, we present a case report of a woman with a history of systemic lupus erythematosus and antiphospholipid syndrome, presenting with concurrent COVID-19 infection and immune thrombotic thrombocytopenic purpura (TTP). The patient was treated with plasma exchange, steroids, and caplacizumab with initial good response to therapy. The course of both TTP and COVID-19 disease was mild. However, after ADAMTS-13 activity was normalized, the patient experienced an early unexpected TTP relapse manifested by intravascular hemolysis with stable platelet counts requiring further treatment. Only 3 cases of COVID-19 associated TTP were reported in the literature thus far. We summarize the literature and suggest that COVID-19 could act as a trigger for TTP, with good outcomes if recognized and treated early.

Download Full-text

Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences?

Nutrients ◽

10.3390/nu13030772 ◽

2021 ◽

Vol 13 (3) ◽

pp. 772

Author(s):

Alessia Alunno ◽

Francesco Carubbi ◽

Elena Bartoloni ◽

Davide Grassi ◽

Claudio Ferri ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Systemic Lupus Erythematosus ◽

Lupus Erythematosus ◽

Musculoskeletal Diseases ◽

Normal Subjects ◽

Experimental Models ◽

Systemic Lupus ◽

History Of ◽

Indirect Action

In recent years, an increasing interest in the influence of diet in rheumatic and musculoskeletal diseases (RMDs) led to the publication of several articles exploring the role of food/nutrients in both the risk of developing these conditions in normal subjects and the natural history of the disease in patients with established RMDs. Diet may be a possible facilitator of RMDs due to both the direct pro-inflammatory properties of some nutrients and the indirect action on insulin resistance, obesity and associated co-morbidities. A consistent body of research has been conducted in rheumatoid arthritis (RA), while studies in systemic lupus erythematosus (SLE) are scarce and have been conducted mainly on experimental models of the disease. This review article aims to outline similarities and differences between RA and SLE based on the existing literature.

Download Full-text